By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received regulatory approval in China to initiate a Phase Ib/II clinical study evaluating its proprietary SHR-3821 in combination with adebrelimab and retlirafusp alfa for the treatment of advanced solid tumors. This triple-combination approach represents a sophisticated immunotherapy strategy leveraging three distinct mechanisms to overcome tumor immune evasion.
Clinical Development Framework
| Component | Development Stage | Mechanism of Action | Regulatory Status |
|---|---|---|---|
| SHR-3821 | Phase Ib/II (novel) | Selective activation of tumor-infiltrating immune cells | First-in-class in China (no approved competitors) |
| Adebrelimab | Approved (Feb 2023) | Anti-PD-L1 monoclonal antibody blocking PD-1/PD-L1 pathway | Approved for extensive-stage SCLC (1L with chemo) |
| Reltirafusp Alfa | Approved (Jan 2026) | PD-L1/TGF-βRII fusion protein dual targeting | Approved for gastric/GEJ adenocarcinoma (1L with chemo) |
Drug Profile & Mechanism of Action
SHR-3821 – Novel Immune Cell Activator
- Molecule: In-house developed antibody drug for advanced solid tumors
- Innovation: First-in-class mechanism in China with no approved competitors targeting the same pathway
- Mechanism: Selectively activates immune cells specifically within tumor tissue microenvironment
- Differentiation: Tumor-localized immune activation potentially reduces systemic toxicity
Adebrelimab – Established PD-L1 Inhibitor
- Molecule: Humanized anti-PD-L1 monoclonal antibody developed independently by Hengrui
- Mechanism: Blocks PD-1/PD-L1 pathway responsible for tumor immune tolerance
- Commercial Status: Already approved in China for first-line extensive-stage small cell lung cancer (February 2023)
Reltirafusp Alfa – Dual-Targeting Fusion Protein
- Molecule: PD-L1/TGF-βRII fusion protein designed for enhanced immune activation
- Dual Mechanism:
- Promotes activation of effector T cells through PD-L1 targeting
- Improves immune regulation in tumor microenvironment via TGF-βRII inhibition
- Recent Approval: January 2026 for first-line gastric/gastroesophageal junction adenocarcinoma with PD-L1 positivity (CPS ≥ 1)
Strategic Rationale for Triple Combination
This innovative combination leverages complementary mechanisms to address multiple layers of tumor immune suppression:
- SHR-3821 provides localized immune cell activation within the tumor
- Adebrelimab removes the primary immune checkpoint blockade (PD-L1)
- Reltirafusp alfa simultaneously targets both PD-L1 and TGF-β pathways, addressing additional immunosuppressive factors in the tumor microenvironment
The triple approach aims to create a synergistic effect that overcomes the limitations of single-agent or dual-combination immunotherapies.
Market Context & Competitive Advantage
China’s Immunotherapy Landscape:
- Rapidly evolving market with increasing adoption of combination immunotherapy approaches
- High unmet need in advanced solid tumors resistant to existing immunotherapies
- Regulatory preference for domestically developed innovative therapies
Hengrui’s Integrated Portfolio Strategy:
- All three components are internally developed, providing complete control over development and commercialization
- Leverages existing commercial infrastructure for adebrelimab and retlirafusp alfa
- First-in-class potential for SHR-3821 creates significant competitive moat
- Triple combination could establish new standard of care if successful
Development Timeline & Commercial Outlook
The Phase Ib/II trial will assess safety, tolerability, and preliminary efficacy of the triple combination. Given the established safety profiles of adebrelimab and retlirafusp alfa, the primary focus will be on determining optimal dosing of SHR-3821 and evaluating synergistic anti-tumor activity.
Success in this trial could position Hengrui to pursue accelerated approval pathways for multiple solid tumor indications, leveraging the company’s growing expertise in combination immunotherapy development.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and therapeutic potential of the triple combination therapy. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive dynamics, and market conditions.-Fineline Info & Tech